Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000, Ljubljana, Slovenia.
Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Mycopathologia. 2018 Apr;183(2):371-380. doi: 10.1007/s11046-017-0214-9. Epub 2017 Oct 24.
To retrospectively investigate the epidemiology of cryptococcosis in Ljubljana, Slovenia.
Forty-six sequentially obtained isolates from 19 patients were subjected to amplified fragment length polymorphism (AFLP) genotyping, microsatellite typing, mating- and serotype PCRs and antifungal susceptibility testing.
Majority of the isolates were Cryptococcus deneoformans (n = 29/46; 63%) followed by Cryptococcus neoformans (n = 16/46; 34.8%) and their interspecies hybrid (n = 1/46; 2.2%). Mating-type α was predominant, two mating-type a C. deneoformans isolates and one mating-type a/α isolate were observed. Several mixed infections were found by microsatellite typing; one patient had a persisting C. deneoformans infection for > 2.5 years. For C. deneoformans, the in vitro antifungal MIC and susceptibility ranges were for amphotericin B 0.25 µg/ml (0.031-0.25 µg/ml), 5-fluorocytosine 0.25 µg/ml (0.063-4 µg/ml), fluconazole 8 µg/ml (0.5-16 µg/ml), voriconazole 0.063 µg/ml (0.008-0.125 µg/ml), posaconazole 0.063 µg/ml (0.008-0.063 µg/ml) and itraconazole 0.063 µg/ml (0.031-0.125 µg/ml). For C. neoformans, these values were for amphotericin B 0.25 µg/ml (0.063-0.5 µg/ml), 5-fluorocytosine 1 µg/ml (0.063-1 µg/ml), fluconazole 16 µg/ml (0.5-64 µg/ml), voriconazole 0.125 µg/ml (0.008-0.25 µg/ml), posaconazole 0.063 µg/ml (0.008-0.063 µg/ml) and itraconazole 0.063 µg/ml (0.031-0.125 µg/ml).
Majority of the cases were caused by C. deneoformans; mating-type α was predominant. Several mixed infections were identified by AFLP genotyping and microsatellite typing. Despite antifungal therapy, a cryptococcal isolate could persist for years. Voriconazole, itraconazole and posaconazole were the most potent antifungal drugs.
回顾性调查斯洛文尼亚卢布尔雅那的隐球菌病流行病学。
对 19 名患者的 46 株连续获得的分离株进行扩增片段长度多态性(AFLP)基因分型、微卫星分型、交配型和血清型 PCR 以及抗真菌药敏试验。
大多数分离株为新型隐球菌(n=29/46;63%),其次为新型隐球菌(n=16/46;34.8%)和它们的种间杂种(n=1/46;2.2%)。主要为交配型α,观察到两个交配型 a 新型隐球菌分离株和一个交配型 a/α 分离株。通过微卫星分型发现了几种混合感染;一名患者持续感染新型隐球菌超过 2.5 年。对于新型隐球菌,体外抗真菌 MIC 和药敏范围为两性霉素 B 0.25μg/ml(0.031-0.25μg/ml)、5-氟胞嘧啶 0.25μg/ml(0.063-4μg/ml)、氟康唑 8μg/ml(0.5-16μg/ml)、伏立康唑 0.063μg/ml(0.008-0.125μg/ml)、泊沙康唑 0.063μg/ml(0.008-0.063μg/ml)和伊曲康唑 0.063μg/ml(0.031-0.125μg/ml)。对于新型隐球菌,这些值分别为两性霉素 B 0.25μg/ml(0.063-0.5μg/ml)、5-氟胞嘧啶 1μg/ml(0.063-1μg/ml)、氟康唑 16μg/ml(0.5-64μg/ml)、伏立康唑 0.125μg/ml(0.008-0.25μg/ml)、泊沙康唑 0.063μg/ml(0.008-0.063μg/ml)和伊曲康唑 0.063μg/ml(0.031-0.125μg/ml)。
大多数病例由新型隐球菌引起;主要为交配型α。通过 AFLP 基因分型和微卫星分型鉴定出几种混合感染。尽管进行了抗真菌治疗,但隐球菌分离株仍可持续多年存在。伏立康唑、伊曲康唑和泊沙康唑是最有效的抗真菌药物。